Protagenic Therapeutics Inc ATRN:NASDAQ

RT Quote | USD
Last | undefined
()
52 week range
0.00 - 0.00
Loading...
  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-

Key Stats

  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

KEY STATS

  • Open-
  • Day High-
  • Day Low-
  • Prev Close-
  • 52 Week High0.00
  • 52 Week High Date-
  • 52 Week Low0.00
  • 52 Week Low Date-
  • Market Cap-
  • Shares Out-
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Protagenic Therapeutics Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Protagenic Therapeutics, Inc. is a biopharmaceutical company specializing in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric...
Garo Armen Ph.D.
Executive Chairman of the Board
Andrew Slee Ph.D.
Chief Operating Officer
Alexander Arrow M.D.
Chief Financial Officer
Address
149 FIFTH AVENUE, SUITE 500
New York, NY
10010
United States